Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma (PRIMAIN)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00989352
Recruitment Status : Unknown
Verified October 2009 by University Hospital Freiburg. Recruitment status was: Recruiting
The purpose of this study is to determine whether combined chemotherapy [rituximab plus high dosage methotrexate, lomustine, and procarbazine] followed by maintenance therapy with procarbazine is effective in the treatment of cerebral Non Hodgkin lymphoma [PCNSL] in patients > 65 years.
Condition or disease
Primary Non Hodgkin Lymphoma of the Central Nervous System
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
65 Years and older (Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
first diagnosis of PCNSL, histologically confirmed
age > 65 years
written signed and dated informed consent of the legal representative and - if possible - of the patient
manifestations of further lymphoma outside the CNS
sero-positive for HIV
severe pulmonary, cardiac, hepatic, renal impairment